<DOC>
	<DOCNO>NCT00002523</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug , give drug different way , combine radiation therapy surgery chemotherapy may kill tumor cell . PURPOSE : Randomized phase III trial compare radiation therapy alone surgery radiation therapy plus fluorouracil leucovorin surgery , without fluorouracil leucovorin surgery patient rectal cancer surgically remove .</brief_summary>
	<brief_title>Radiation Therapy , Surgery , Chemotherapy Treating Patients With Rectal Cancer That Can Be Surgically Removed</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free overall survival patient resectable adenocarcinoma rectum treat preoperative radiotherapy without preoperative fluorouracil ( 5-FU ) combine leucovorin calcium ( CF ) and/or postoperative 5-FU/CF . OUTLINE : This randomize , multicenter study . Patients stratify accord center , sex , tumor location ( 0-5 v 6-10 vs 11-15 cm anal margin ) , stage ( T3 v T4 ) . Patients randomize 1 4 treatment arm . - Arm I : Patients undergo involved-field radiotherapy 5 day week 5 week follow 3-10 week later abdominoperineal resection anal-sparing resection accord local practice absence disease progression unacceptable toxicity . - Arm II : Patients undergo radiotherapy arm I begin day 1 leucovorin calcium ( CF ) IV follow fluorouracil ( 5-FU ) IV ( 1 hour radiotherapy ) day 1-5 29-33 , follow 3-10 week later resection arm I absence disease progression unacceptable toxicity . - Arm III : Patients undergo radiotherapy follow 3-10 week later resection arm I . Within 3-10 week resection , patient receive CF follow 5-FU day 1-5 . Chemotherapy continue every 4 week 4 course absence disease progression unacceptable toxicity . - Arm IV : Patients undergo preoperative radiotherapy concurrent chemotherapy follow resection arm II postoperative chemotherapy arm III . Patients follow every 6 month . PROJECTED ACCRUAL : A total 992 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm resectable adenocarcinoma rectum Any grade Tumor macroscopically within 15 cm anal margin rigid rectoscopy Tumor tether partially fix digital rectal exam and/or T34 rectal ultrasound No acute subacute bowel obstruction without colostomy diversion No chronic inflammatory disease ileum and/or colon No primary adenocarcinoma anal canal No distant metastasis PATIENT CHARACTERISTICS : Age : 80 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : Granulocyte count great 2,000/mm^3 Platelet count great 130,000/mm^3 Hepatic : Not specify Renal : Creatinine le 1.36 mg/dL Cardiovascular : No angina pectoris Other : No prior malignancy except basal cell skin cancer carcinoma situ uterine cervix PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy adenocarcinoma rectum Chemotherapy No prior chemotherapy adenocarcinoma rectum Endocrine therapy No prior endocrine therapy adenocarcinoma rectum Radiotherapy No prior radiotherapy adenocarcinoma rectum Surgery No prior surgery adenocarcinoma rectum</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>